Luca Parolari

Senior Associate

2021 - Current

Selected investments: SoluTx (Seed), Latus Bio (Series A), Auron (Series A), Umoja (Series B), Avicenna (Seed), Totus Medicine (Series B), Plexium (Series B), Novome (Series B), Cellanome (Series A, A2), Syntax (Seed), Stemson (Series A), CH4 Global (Series A). Due diligence, portfolio management, sourcing, landscape research. - Financial and deep technical diligence on 2 dozen companies. - Operational support to 3 in-house incubations. Attending BoD as an unofficial Board Observer for 5 portcos. Providing portcos with operational and strategic assistance, fundraising support. - Sourced an average of 1,000 companies/year from personal network, conferences, accelerators. - Deep dive research on Allogeneic Cell Therapy, Bispecific Antibodies, Autoimmune Diseases, Neurodegenerative, Psychedelic Medicines, Drug Delivery of Genetic Medicines, AI/ML in Drug Discovery, RNA Medicines. DCVC Bio is an SF-based early-stage venture capital firm investing in companies at the intersection of computation and life science. Our focus is on therapeutics, synthetic biology, industrial biotech, and agricultural tech, with a particular interest in companies developing revolutionary machine learning-powered platforms. Currently investing out of a $600M fund (Core + Opp).

Co-Founder & Director

2017

Contemporary Art Gallery promoting cultural diplomacy between East and West: - Southeast Asian and Philippine contemporary art gallery in Manhattan's East Village. - Offsite art exhibits globally: New York (West Village & TriBeCa: chaired by David Rockefeller and Donna Karan), Tokyo (chaired by Japan and Philippines Ambassadors), Milan; upcoming: Madrid. - Art fairs: Untitled at Art Basel, Miami Beach. - Monthly salon-type events in EV gallery: fostering international community of scientists, journalists, artists, entrepreneurs, entertainment professionals.

VC Fellow

2020 - 2021

Sourcing and Due Diligence for Early Stage Investment Firm with a Mission to Improve & Advance Human Health (Health-tech, Biotech, Synbio, Neurotech, AR, AI, Quantum).

Postdoctoral Researcher

2020 - 2020

Researcher PhD Student

2014 - 2020

Jeff Friedman Lab (Lasker Awardee) Paul Greengard Lab (Nobel Laureate) Fields: Molecular & Cellular Biology, Genetics & Genomics, Systems & Behavioral Neuroscience Topics: OCD, Parkinson, Obesity, Thermoregulation Publications: 1st Author on Cell (impact factor 36), Mol Psychiatry (IF 12)

Fellow & VP Operations

2018 - 2019

Leadership development program in the startup, technology, entrepreneurial and VC space, comprised of select graduate students at top universities, including Columbia, NYU, Harvard, MIT, Stanford.

Future Angel

2018 - 2018

New York's angel investment network comprised of over 100 active members, made up of entrepreneurs, CEO's, venture capitalists and business leaders who have founded, funded and built world-class companies.

BIF Fellow @ Rockefeller University

2016 - 2018

100,000$ salary grant over 3 years for biomedical research

Medical Student

2014 - 2014

Exchange Medical Student Sub-i in Neurosurgery, Neurology, Medicine Massachusetts General Hospital, Brigham Women's Hospital (actual dates differ, split over the course of 3 years)

Medical Student

2014 - 2014

Exchange Medical Student in Neurology for 1 month

Researcher Medical Student for 1 year

2013 - 2013

Exchange Medical Student